Zhao et al., 2004 - Google Patents

Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus

Zhao et al., 2004

View PDF
Document ID
390952013069442451
Author
Zhao Y
Guan D
Song M
Liu J
Fu G
Publication year
Publication venue
Transplantation

External Links

Snippet

Aims: The calcineurin inhibitors cyclosporine and tacrolimus are the major immunosuppressive agents, It becomes complicated to use them for their interindividual differences in the oral bioavailability. CYP3A is the major enzyme responsible for …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material

Similar Documents

Publication Publication Date Title
Zhao et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus
Kumashiro et al. Isolation of hepatocyte-like cells from mouse embryoid body cells
Bos et al. RENAL EXPRESSION OF HEAT-SHOCK PROTEINS AFTER BRAIN DEATH INDUCTION IN RATS
Grubic et al. THE EVALUATION OF MIXED CHIMERISM IN BONE MARROW TRANSPLANTATION PROGRAM IN CROATIA
Hsu et al. Enhancing islet engraftment with rosiglitazone
Interewicz et al. DNA RELEASED FROM REJECTING ORGANS IS AN INDICATOR OF THE DEGREE OF GRAFTCELLULAR DAMAGE
Gotoh et al. Ultrasound-mediated nonviral ex vivo gene transfer into liver graft
Takenouchi et al. THE MECHANISM OF IMMUNOSUPPRESSIVE EFFECT IN VIVO OF NOVEL IMMUNOSUPPRESSIVE DRUG, Β-SQAG9 THAT INHIBITS THE RESPONSE OF CD62L+ T CELL SUBSET
Hu et al. Surveillance Of Acute Rejection In Baboon Renal Transplantation By Elevation Of Ip-10 And Mig In Urine
Witkowski et al. EFFECT OF STREPTAVIDIN ON CARDIAC ALLOGRAFT PROLONGATION IS DUE TO HOST T CELL SUPPRESSION.
Suzuki et al. A NONVIRAL GENE TRANSFER USING THE ULTRASOUND-MICROBUBBLE METHOD HAS ENHANCED TRANSFECTION EFFICIENCY OF NF-κB DECOY INTO MURINE CARDIAC ALLOGRAFTS
Lu et al. ICOS/B7RP-1 MODULATING SUBSTANCES IN A MOUSE MODEL OF KIDNEY TRANSPLANTATION
Brandacher et al. INHIBITION OF THE IMMUNOMODULATORY ENZYME INDOLEAMINE 2, 3–DIOXYGENASE ACCELERATES ALLOGRAFT REJECTION.
Bueno et al. FTY720 DOES NOT PREVENT MESANGIAL CELL ACTIVATION BUT IMPAIRS NECROSIS DEVELOPMENT AFTER ISCHEMIA-REPERFUSION (I/R) INJURY.
Kramer et al. ES CELL-DERIVED RENAL CELL TYPES: A TOOL FOR TISSUE REGENERATION?
Shimizu et al. COMBINATION THERAPY OF KRP-203, A NOVEL SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST, WITH CYCLOSPORINE ABROGATES ACUTE REJECTION WITHOUT ADVERSE EFFECTS–A COMPARATIVE STUDY WITH FTY720–
Koch et al. CHRONIC ALLOGRAFT NEPHROPATHY IN A RAT MODEL WITH COMPLETE MHC MISMATCH: EFFECTS OF THERAPEUTIC TREATMENT WITH FTY 720
Suleiman et al. FTY720 TREATMENT PREVENTS RENAL T CELL INFILTRATION AFTER ISCHEMIA-REPERFUSION (I/R) INJURY.
Ding et al. Urinary cell messenger RNA profiles predict allograft outcome in patients with BKV nephropathy
Ferencz et al. THE ROLE OF NF-KB TO MODIFY THE OXIDATIVE STRESS IN SMALL BOWEL AUTOTRANSPLANTATION MODEL
Lloberas et al. DIFFERENT FUNCTIONAL, HISTOLOGICAL AND INMUNOHISTOCHEMICAL PATTERNS INDUCED BY THE ASSOCIATION OF RAPAMYCIN WITH FK506 OR CYCLOSPORINE.
Fujishiro et al. EFFICIENCY OF ADENOVIRUS-MEDIATED GENE TRANSDUCTION ON VARIOUS GRAFT ORGANS IN RATS
Maglione et al. THE NOVEL INOS-INHIBITOR 4-AMINO-TETRAHYDROBIOPTERIN ACTS AS POWERFUL IMMUNOSUPPRESSANT: GENE EXPRESSION ANALYSIS USING CDNA MICROARRAY TECHNOLOGY.
Vampa et al. NK CELLS ARE PREDOMINANT SOURCE OF γIFN: INHIBITION BY CYCLOSPORINE, TACROLIMUS, MMF, STEROID AND AZATHIOPRINE
Savikko et al. The Effect Cyclosporine on Chronic Allograft Changes in Syngenic Kidney Transplants